SCHEMBL14977858

SCHEMBL14977858

Cn1nnnc1Cn1nc2nc(C(C)(C)C)nc(N3CCC(C)(O)C3)c2n1

nearest known ligand 0.51

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 20/20 0.51
CNR1 P21554 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14973883 1.00 CNR2 (0.51) CNR2CNR1
SCHEMBL14974342 1.00 CNR2 (0.51) CNR2CNR1
SCHEMBL14977326 0.88 CNR2 (0.53) CNR2CNR1
SCHEMBL14974007 0.88 CNR2 (0.53) CNR2CNR1
SCHEMBL14974530 0.88 CNR2 (0.53) CNR2CNR1
SCHEMBL14974256 0.88 CNR2 (0.66) CNR2CNR1
SCHEMBL14974462 0.83 CNR2 (0.63) CNR2CNR1
SCHEMBL14911990 0.82 CNR2 (0.59) CNR2CNR1
SCHEMBL14911639 0.82 CNR2 (0.59) CNR2CNR1
SCHEMBL14911644 0.82 CNR2 (0.59) CNR2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2782915-A1 [1, 2, 3]TRIAZOLO [4, 5 -D]PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2014-10-01 EP claimed
WO-2013076182-A1 [1, 2, 3]TRIAZOLO [4, 5 -D] PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2013-05-30 WO claimed
EP-2782915-A1 [1, 2, 3]TRIAZOLO [4, 5 -D]PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2014-10-01 EP disclosed
WO-2013076182-A1 [1, 2, 3]TRIAZOLO [4, 5 -D] PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2013-05-30 WO disclosed